LBA20: Sacituzumab govitecan significantly prolongs PFS versus chemotherapy in advanced triple-negative breast cancer

Results from a late-breaking abstract presented at ESMO 2025 suggest that sacituzumab govitecan may establish a new standard of care for patients with advanced triple-negative breast cancer (TNBC).